Scottish Medicines Consortium Recommends Roche’s Perjeta

The Scottish Medicines Consortium recommended Roche’s breast cancer treatment Perjeta (pertuzumab) for use through the National Health Service, following the drugmaker’s third resubmission of the drug.

Previously recommended by NICE, the drug is for use in combination with trastuzumab and docetaxel by adults with HER2 positive metastatic or locally recurrent unresectable breast cancer who haven’t previously had anti-HER2 therapy or chemotherapy.

The SMC said that the addition of Perjeta, in combination with the current first-line treatment, trastuzumab plus docetaxel, significantly increased progression-free and overall survival for women with the disease.